Cargando…

PB2002: ASSOCIATION OF GENE MUTATIONS AND CLINICAL MANIFESTATIONS AND PROGNOSIS IN THE CLINICAL COHORT WITH 218 MDS PATIENTS

Detalles Bibliográficos
Autores principales:	Wang, Xue’e, Wang, Peixuan, Gu, Yan, Hou, Yue, Ge, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430369/ http://dx.doi.org/10.1097/01.HS9.0000974824.52328.61

Ejemplares similares

PB2006: MOLECULAR CLINICAL CHARACTERISTICS AND PROGNOSIS OF MDS PATIENTS WITH RUNX1 MUTATION
por: Huang, Nanfang, et al.
Publicado: (2023)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

PB2016: HIGH SERUM FERRITIN LEVELS AT DIAGNOSIS PREDICT WORSE PROGNOSIS IN ADVANCED MDS IN CHILDREN.
por: Liu, Chenmeng, et al.
Publicado: (2023)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PB2032: FACTORS ASSOCIATED WITH TRANSFUSION INDEPENDENCY POST TREATMENT IN HIGH RISK MDS PATIENTS
por: Fatima, Naveena, et al.
Publicado: (2023)

PB1989: STUDY ON THE RELATIONSHIP BETWEEN MDS AND ABNORMAL LIPID METABOLISM IN BONE MARROW MICROENVIRONMENT
por: LI, Yuchun, et al.
Publicado: (2023)

PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
por: de Botton, Stéphane, et al.
Publicado: (2023)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

PB2402: CLINICAL CHARACTERISTICSAND PROGNOSIS RISK FACTORS OF NON-HODGKIN’S LYMPHOMA INVOLVING THE HEART
por: Chen, Yue, et al.
Publicado: (2023)

PB2107: CLINICAL MANIFESTATIONS AND EFFICACY ANALYSIS OF 71 CASES OF AIDS-RELATED LYMPHOMA
por: Liu, J., et al.
Publicado: (2022)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
por: DeZern, A., et al.
Publicado: (2022)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

PB2023: THE LEVEL OF VASCULAR ENDOTHELIAL FACTOR (VEGF) IN THE BLOOD SERUM OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS RAEB I).
por: Стародуб, Галина, et al.
Publicado: (2023)

PB1919: S100A9 DEFICIENCY ACCELERATES MDS ASSOCIATED TUMOR ESCAPE VIA PD-1/PD-L1 OVEREXPRESSION
por: Wang, R., et al.
Publicado: (2022)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
por: Rajakumaraswamy, N., et al.
Publicado: (2022)

PB1991: NEW MONOCYTE HEMATOLOGICAL PARAMETERS AS AN IMPORTANT INDICATOR OF MDS PATIENTS WITH POSITIVE OGATA SCORE - A PRELIMINARY STUDY
por: Dudzik, Alicja, et al.
Publicado: (2023)

PB2367: CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMA
por: Yahia, Noura Ben, et al.
Publicado: (2023)

PB1925: VENETOCLAX IN COMBINATION WITH AZACITIDINE OR LOW-DOSE CYTARABINE IN PATIENTS WITH HIGH-RISK MDS AND AML - EXPERIENCE OF A CZECH HAEMATOLOGY CENTRE.
por: Minarik, L., et al.
Publicado: (2022)

PB1946: NOTCH PATHWAY MUTATION CONTRIBUTES TO INFERIOR PROGNOSIS IN HBV-INFECTED CHRONIC LYMPHOCYTIC LEUKEMIA
por: Shang, Chunyu, et al.
Publicado: (2023)

PB2418: CLINICAL FEATURES AND PROGNOSIS OF ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Sun, Wei, et al.
Publicado: (2023)

PB1942: HEPATIC MANIFESTATIONS OF CHILDHOOD HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS
por: El Sayed, M., et al.
Publicado: (2022)

PB1765: DIFFERENTIAL GENE EXPRESSION PROFILE IN DNA DAMAGE SIGNALING PATHWAYS, IN DE NOVO ACUTE MYELOID LEUKEMIA AND LOW-RISK MDS PATIENTS
por: Bouchla, Anthi, et al.
Publicado: (2023)

PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
por: Mukherjee, S., et al.
Publicado: (2022)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Komrokji, Rami S., et al.
Publicado: (2023)

PB1800: CLINICAL CHARACTERISTICS AND MUTATION LANDSCAPE OF TRISOMY AML
por: Lam, Stephen S Y, et al.
Publicado: (2023)

PB2030: HYPERCHROMIC ANEMIA AS THE FIRST MANIFESTATION OF MYELOPROLIFERATIVE DISEASE
por: Lepkov, Sergey, et al.
Publicado: (2023)

PB1770: CHARACTERIZATION OF THE MUTATIONAL PROFILE OF PATIENTS WITH CBF-AML - HETEROGENEITY AND IMPACT ON THE PROGNOSIS
por: Motyko, Ekaterina, et al.
Publicado: (2023)

PB1811: BIOLOGIC AND CLINICAL SIGNIFICANCE OF CD7 ABERRANT EXPRESSION IN ACUTE MYELOID LEUKEMIA: A POOR PROGNOSIS MARKER
por: Charfi, H., et al.
Publicado: (2022)

PB1894: NPM1 MUTATED ACUTE MYELOID LEUKEMIA: THE CO-MUTATION PATTERNS MAY BE ASSOCIATED WITH PROGNOSIS
por: Varelas, Christos, et al.
Publicado: (2023)

PB2124: MYC EXPRESSION ANALYSIS AND PROGNOSIS VALUE IN TRANSFORMED FOLLICULAR LYMPHOMA
por: Liang, J., et al.
Publicado: (2022)

PB2217: REAL-WORLD RESEARCH OF CLINICAL AND HEMATOLOGIC NEOPLASMS RELATED GENETIC MUTATIONS IN 275 POLYCYTHEMIA VERA PATIENTS
por: Zhang, Lan, et al.
Publicado: (2023)

PB2190: COMORBIDITIES PREDICT WORSE PROGNOSIS IN PATIENTS WITH POLYCYTHEMIA VERA
por: Arsenović, Isidora, et al.
Publicado: (2023)

PB2055: PREGNANCY IN PATIENTS WITH APLASTIC ANEMIA – CLINICAL OBSERVATIONS
por: Shilova, Elene, et al.
Publicado: (2023)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2002: OBSERVATIONAL PROSPECTIVE STUDY TO INVESTIGATE THE RELATIONSHIP BETWEEN DURATION OF TREATMENT AND RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA OR AL AMYLOIDOSIS: THE DORIANT STUDY (NCT: 04659798)
por: Grande, M., et al.
Publicado: (2022)

PB1784: CLADRIBINE SYNERGIZES THE EFFECT OF VENETOCLAX ON CELL PROLIFERATION ARREST AND APOPTOSIS BY TARGETING DNA-PKCS/C-MYC SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Hou, Yue, et al.
Publicado: (2023)

PB2332: CLINICAL CHARACTERISTICS AND OUTCOMES OF HIV-ASSOCIATED AGGRESSIVE B-CELL NHL IN CHINA
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
por: Abdul-Hay, Maher, et al.
Publicado: (2023)

PB1859: DNMT3A MUTATION PATTERNS AND CLINICAL FEATURES IN KOREAN ACUTE MYELOID LEUKEMIA PATIENTS
por: Lee, Eunyoung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4nb92ruqlidchrap030ep490it